查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591977

免疫查核点抑制剂市场：按类型、适应症、给药途径、最终用户、分销管道 - 全球预测 2025-2030

Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Route of Administration, End-Users, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

免疫查核点抑制剂市场2023年估值为94.7亿美元，预计2024年将达到104.6亿美元，复合年增长率为10.82%，到2030年将达到194.6亿美元。

免疫查核点抑制剂市场的范围和定义围绕着旨在帮助免疫系统更有效地识别和攻击癌细胞的药物。这些抑制剂以 PD-1、PD-L1 和 CTLA-4 等蛋白质为目标，通常会抑制免疫系统的活动，使其不会攻击癌细胞。越来越多的癌症（包括黑色素瘤、肺癌和肾癌）推动了对这些抑制剂的需求，这些癌症需要比传统化疗和放射线治疗更有效的治疗方法。免疫查核点抑制剂疗法主要针对肿瘤学，为免疫疗法治疗癌症带来新的希望。最终用途范围包括医院、癌症研究机构和专科诊所，这些药物主要在这些地方进行管理和研究。

主要市场统计
基准年[2023] 94.7亿美元
预测年份 [2024] 104.6亿美元
预测年份 [2030] 194.6亿美元
复合年增长率（%） 10.82%

根据市场洞察，生物技术的进步、新药的监管核准以及癌症研究投资的增加是关键的成长要素。市场正在见证透过可以提高治疗效果的个人化医疗和联合治疗的成长机会。对企业来说，与研究机构合作、投资临床试验是抓住新机会的途径。然而，治疗成本高、潜在副作用和患者反应有限等限制因素给市场扩张带来了挑战。来自其他治疗方法的监管障碍和竞争压力也构成了威胁。

创新的可能性包括探索非肿瘤应用、增强递送机制和减少副作用，这可能开闢新的途径。研究预测生物标记以确定可能对治疗有反应的患者可以显着优化治疗结果。儘管本质上竞争激烈，但该市场为旨在改善患者特异性治疗策略和扩大治疗覆盖范围的创新提供了肥沃的土壤。鑑于进展速度之快，研发方面的策略联盟和合作对于持续成长和竞争优势至关重要。

市场动态：快速发展的免疫查核点抑制剂市场的关键市场洞察

免疫查核点抑制剂市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症盛行率不断上升
    • 政府不断加强癌症治疗和意识提升计划
    • 老年人口不断增长，生活方式不健康
  • 市场限制因素
    • 对免疫查核点抑制剂的副作用、高成本和疗效的担忧
  • 市场机会
    • 先进癌症治疗的持续研究活动
    • 新型免疫查核点抑制剂的监管核准增加
  • 市场挑战
    • 癌症替代治疗方法的存在

波特五力：驾驭免疫查核点抑制剂市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解免疫查核点抑制剂市场的外部影响

外部宏观环境因素在塑造免疫查核点抑制剂市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解免疫查核点抑制剂市场的竞争格局

对免疫查核点抑制剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵免疫查核点抑制剂市场供应商的绩效评估

FPNV 定位矩阵是评估免疫查核点抑制剂市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了免疫查核点抑制剂市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，免疫查核点抑制剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率增加
      • 政府加大对癌症治疗和宣传计划的承诺
      • 老年人口不断增加，生活方式不健康
    • 抑制因素
      • 对免疫查核点抑制剂的相关副作用、高成本和功效的担忧
    • 机会
      • 正在进行的先进癌症治疗研究活动
      • 新型免疫查核点抑制剂的监管核准增加
    • 任务
      • 癌症替代治疗方法的存在
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章免疫查核点抑制剂市场：依类型

  • CTLA-4抑制剂
  • PD-1抑制剂
  • PD-L1抑制剂

第七章依适应症分類的免疫查核点抑制剂市场

  • 膀胱癌
  • 乳癌
  • 子宫颈癌
  • 何杰金氏淋巴瘤
  • 肾癌
  • 肝癌
  • 肺癌
  • 固体癌

第八章免疫查核点抑制剂市场：依给药途径

  • 口服
  • 胃肠外的

第九章免疫查核点抑制剂市场：依最终用户分类

  • 医院
  • 专科诊所

第10章免疫查核点抑制剂市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第十一章美洲免疫查核点抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太免疫查核点抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲免疫查核点抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alphamab Oncolog
  • ALX Oncology Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • GlaxoSmithKline PLC
  • ImmuneSensor Therapeutics Inc.
  • ImmunityBio, Inc.
  • Kintor Pharmaceutical Limited
  • Merck KGaA
  • MiNK Therapeutics, Inc.
  • NATCO Pharma Ltd.
  • NextCure, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Seagen Inc.
  • SQZ Biotechnologies Company
  • Thermo Fisher Scientific Inc.
  • Xencor, Inc.
Product Code: MRR-FF012EDC38BE

The Immune Checkpoint Inhibitors Market was valued at USD 9.47 billion in 2023, expected to reach USD 10.46 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 19.46 billion by 2030.

The scope and definition of the immune checkpoint inhibitors market revolve around drugs designed to help the immune system recognize and attack cancer cells more effectively. These inhibitors target proteins, such as PD-1, PD-L1, and CTLA-4, which typically suppress immune system activity to prevent it from attacking cancer cells. The necessity for these inhibitors is driven by the increasing prevalence of various cancers, including melanoma, lung, and renal cancers, that require more effective treatment options beyond traditional chemotherapy and radiation. Applications of immune checkpoint inhibitors are largely focused on oncology, providing new hope in immunotherapy for cancer treatment. The end-use scope includes hospitals, cancer research institutes, and specialty clinics, where these drugs are predominantly administered and studied.

KEY MARKET STATISTICS
Base Year [2023] USD 9.47 billion
Estimated Year [2024] USD 10.46 billion
Forecast Year [2030] USD 19.46 billion
CAGR (%) 10.82%

Market insights reveal that significant growth factors include advancements in biotechnology, approval of new drugs by regulatory bodies, and increasing investments in cancer research. The market is witnessing growth opportunities through personalized medicine and combination therapies, which can enhance treatment efficacy. For businesses, collaborating with research institutions and investing in clinical trials offer ways to seize emerging opportunities. However, limitations such as high treatment costs, potential adverse effects, and limited patient response challenge market expansion. Regulatory hurdles and competitive pressures from other treatment modalities also pose threats.

For innovative potential, exploring non-oncological applications, enhancing delivery mechanisms, and reducing adverse effects can pave new paths. Research into predictive biomarkers to identify patients most likely to respond to therapy can significantly optimize treatment outcomes. The market is inherently competitive but provides fertile ground for innovation aimed at improving patient-specific treatment strategies and broadening therapeutic applicability. Given the rapid pace of advancements, strategic alliances and collaborations in research and development will be crucial for sustained growth and gaining a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immune Checkpoint Inhibitors Market

The Immune Checkpoint Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer across the globe
    • Rising government initiatives for cancer treatment and awareness programs
    • Growing geriatric population and adoption of unhealthy lifestyle
  • Market Restraints
    • Associated side effects, high cost and efficacy concerns of immune checkpoint inhibitors
  • Market Opportunities
    • Ongoing research activities for advanced cancer treatments
    • Rise in approvals of novel immune checkpoint inhibitors from regulatory bodies
  • Market Challenges
    • Presence of alternative treatment therapies for cancer

Porter's Five Forces: A Strategic Tool for Navigating the Immune Checkpoint Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immune Checkpoint Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immune Checkpoint Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immune Checkpoint Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immune Checkpoint Inhibitors Market

A detailed market share analysis in the Immune Checkpoint Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immune Checkpoint Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immune Checkpoint Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immune Checkpoint Inhibitors Market

A strategic analysis of the Immune Checkpoint Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immune Checkpoint Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alphamab Oncolog, ALX Oncology Inc., Astellas Pharma Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, ImmuneSensor Therapeutics Inc., ImmunityBio, Inc., Kintor Pharmaceutical Limited, Merck KGaA, MiNK Therapeutics, Inc., NATCO Pharma Ltd., NextCure, Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Seagen Inc., SQZ Biotechnologies Company, Thermo Fisher Scientific Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Immune Checkpoint Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor.
  • Based on Indication, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Hodgkin Lymphoma, Kidney Cancer, Liver Cancer, Lung Cancer, and Solid Cancer.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on End-Users, market is studied across Hospitals and Specialty Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer across the globe
      • 5.1.1.2. Rising government initiatives for cancer treatment and awareness programs
      • 5.1.1.3. Growing geriatric population and adoption of unhealthy lifestyle
    • 5.1.2. Restraints
      • 5.1.2.1. Associated side effects, high cost and efficacy concerns of immune checkpoint inhibitors
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities for advanced cancer treatments
      • 5.1.3.2. Rise in approvals of novel immune checkpoint inhibitors from regulatory bodies
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of alternative treatment therapies for cancer
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immune Checkpoint Inhibitors Market, by Type

  • 6.1. Introduction
  • 6.2. CTLA-4 Inhibitor
  • 6.3. PD-1 Inhibitor
  • 6.4. PD-L1 Inhibitor

7. Immune Checkpoint Inhibitors Market, by Indication

  • 7.1. Introduction
  • 7.2. Bladder Cancer
  • 7.3. Breast Cancer
  • 7.4. Cervical Cancer
  • 7.5. Hodgkin Lymphoma
  • 7.6. Kidney Cancer
  • 7.7. Liver Cancer
  • 7.8. Lung Cancer
  • 7.9. Solid Cancer

8. Immune Checkpoint Inhibitors Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Immune Checkpoint Inhibitors Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Immune Checkpoint Inhibitors Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Immune Checkpoint Inhibitors Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Immune Checkpoint Inhibitors Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Immune Checkpoint Inhibitors Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alphamab Oncolog
  • 2. ALX Oncology Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. BioNTech SE
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol-Myers Squibb
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. F. Hoffmann-La Roche AG
  • 12. Genmab A/S
  • 13. GlaxoSmithKline PLC
  • 14. ImmuneSensor Therapeutics Inc.
  • 15. ImmunityBio, Inc.
  • 16. Kintor Pharmaceutical Limited
  • 17. Merck KGaA
  • 18. MiNK Therapeutics, Inc.
  • 19. NATCO Pharma Ltd.
  • 20. NextCure, Inc.
  • 21. Regeneron Pharmaceuticals Inc.
  • 22. Sanofi SA
  • 23. Seagen Inc.
  • 24. SQZ Biotechnologies Company
  • 25. Thermo Fisher Scientific Inc.
  • 26. Xencor, Inc.

LIST OF FIGURES

  • FIGURE 1. IMMUNE CHECKPOINT INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNE CHECKPOINT INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SOLID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 240. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023